Prospective Evaluation of the Utility of Whole Exome Sequencing in Dilated Cardiomyopathy
Open Access
- 21 January 2020
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 9 (2) , e013346
Abstract
Background: Dilated cardiomyopathy may be heritable but shows extensive genetic heterogeneity. The utility of whole exome sequencing as a first‐line genetic test for patients with dilated cardiomyopathy in a contemporary “real‐world” setting has not been specifically established. Using whole exome sequencing with rigorous, evidence‐based variant interpretation, we aimed to identify the prevalence of a molecular diagnosis in patients with dilated cardiomyopathy in a clinical setting. Methods and Results: Whole exome sequencing was performed in eligible patients (n=83) with idiopathic or familial dilated cardiomyopathy. Variants were prioritized for curation in up to 247 genes and classified using American College of Medical Genetics and Genomics–based criteria. Ten (12%) had a pathogenic or likely pathogenic variant. Eight (10%) participants had truncating TTN variants classified as variants of uncertain significance. Five (6%) participants had variants of unknown significance according to strict American College of Medical Genetics and Genomics criteria but classified as either pathogenic or likely pathogenic by other clinical laboratories. Pathogenic or likely pathogenic variants were found in 8 genes (all within tier 1 genes), 2 (20%) of which are not included in a standard commercially available dilated cardiomyopathy panel. Using our bioinformatics pipeline, there was an average of 0.74 variants of uncertain significance per case with ≈0.75 person‐hours needed to interpret each of these variants. Conclusions: Whole exome sequencing is an effective diagnostic tool for patients with dilated cardiomyopathy. With stringent classification using American College of Medical Genetics and Genomics criteria, the rate of detection of pathogenic variants is lower than previous reports. Efforts to improve adherence to these guidelines will be important to prevent erroneous misclassification of nonpathogenic variants in dilated cardiomyopathy genetic testing and inappropriate cascade screening.Keywords
This publication has 42 references indexed in Scilit:
- Toward an effective exome-based genetic testing strategy in pediatric dilated cardiomyopathyGenetics in Medicine, 2018
- Recommendations for interpreting the loss of function PVS1 ACMG/AMP variant criterionHuman Mutation, 2018
- Genome sequencing as a first-line genetic test in familial dilated cardiomyopathyGenetics in Medicine, 2018
- Prospective comparison of the cost-effectiveness of clinical whole-exome sequencing with that of usual care overwhelmingly supports early use and reimbursementGenetics in Medicine, 2017
- Analyses of more than 60,000 exomes questions the role of numerous genes previously associated with dilated cardiomyopathyMolecular Genetics & Genomic Medicine, 2016
- Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular PathologyGenetics in Medicine, 2015
- MutationTaster2: mutation prediction for the deep-sequencing ageNature Methods, 2014
- SIFT web server: predicting effects of amino acid substitutions on proteinsNucleic Acids Research, 2012
- LOVD v.2.0: the next generation in gene variant databasesHuman Mutation, 2011
- Inherited and de novo Mutations in the Cardiac Actin Gene Cause Hypertrophic CardiomyopathyJournal of Molecular and Cellular Cardiology, 2000